Last reviewed · How we verify

NCT04725188

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Completed Phase 2 Results posted Last updated 15 August 2025
What this trial tests

Phase 2 trial testing Pembrolizumab/Vibostolimab coformulation in Metastatic Non Small Cell Lung Cancer in 255 participants. Completed in 17 October 2024.

Timeline
20 April 2021
Primary endpoint
26 January 2023
17 October 2024

Quick facts

Lead sponsorMerck Sharp & Dohme LLC
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment255
Start date20 April 2021
Primary completion26 January 2023
Estimated completion17 October 2024
Sites95 locations across Italy, Finland, Malaysia, Taiwan, Poland, South Korea, Denmark, Russia

Drugs / interventions tested

Conditions studied

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Metastatic Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment Primary · Up to approximately 21 months

PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.

GroupValue95% CI
Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel5.63.9 – 6.8
Arm 2: Pembrolizumab/Vibostolimab Coformulation2.71.8 – 4.0
Arm 3: Placebo + Docetaxel3.22.8 – 5.7
Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment Secondary · Up to approximately 21 months

ORR is defined as the percentage of participants who have a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.

GroupValue95% CI
Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel29.920.5 – 40.6
Arm 2: Pembrolizumab/Vibostolimab Coformulation6.02.0 – 13.5
Arm 3: Placebo + Docetaxel15.38.4 – 24.7
Overall Survival (OS) Secondary · Up to approximately 21 months

OS is defined as the time from randomization to the date of death due to any cause.

GroupValue95% CI
Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel10.28.6 – 14.9
Arm 2: Pembrolizumab/Vibostolimab Coformulation7.55.2 – 13.4
Arm 3: Placebo + Docetaxel8.86.4 – 11.1
Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment Secondary · Up to approximately 21 months

For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assess

GroupValue95% CI
Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel6.55.3 – 10.7
Arm 2: Pembrolizumab/Vibostolimab CoformulationNA2.8 – NA
Arm 3: Placebo + DocetaxelNA3.0 – NA
Number of Participants Who Experienced an Adverse Event (AE) Secondary · Up to approximately 39 months

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported here.

GroupValue95% CI
Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel85
Arm 2: Pembrolizumab/Vibostolimab Coformulation76
Arm 3: Placebo + Docetaxel82
Number of Participants Who Discontinued Study Treatment Due to an AE Secondary · Up to approximately 27 months

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.

GroupValue95% CI
Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel42
Arm 2: Pembrolizumab/Vibostolimab Coformulation12
Arm 3: Placebo + Docetaxel24

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to approximately 39 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Pembrolizumab/Vibostolimab Coformulation + Docetaxel
Serious: 48/85 (56%)
Deaths: 74/87
Pembrolizumab/Vibostolimab Coformulation
Serious: 26/83 (31%)
Deaths: 70/83
Placebo + Docetaxel
Serious: 37/83 (45%)
Deaths: 77/85

Serious adverse events (123 terms)

ReactionSystemPembrolizumab/Vibostolimab…Pembrolizumab/Vibostolimab…Placebo + Docetaxel
PneumoniaInfections and infestations
AnaemiaBlood and lymphatic system disorders
Febrile neutropeniaBlood and lymphatic system disorders
DiarrhoeaGastrointestinal disorders
COVID-19Infections and infestations
Septic shockInfections and infestations
Hip fractureInjury, poisoning and procedural complications
Cardiac failureCardiac disorders
HypophysitisEndocrine disorders
GastritisGastrointestinal disorders
DeathGeneral disorders
Oedema peripheralGeneral disorders
COVID-19 pneumoniaInfections and infestations
Neutrophil count decreasedInvestigations
DehydrationMetabolism and nutrition disorders
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders
DyspnoeaRespiratory, thoracic and mediastinal disorders
HaemoptysisRespiratory, thoracic and mediastinal disorders
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders
Pleural effusionRespiratory, thoracic and mediastinal disorders
Pulmonary embolismRespiratory, thoracic and mediastinal disorders
Drug eruptionSkin and subcutaneous tissue disorders
Superior vena cava syndromeVascular disorders
Acute myocardial infarctionCardiac disorders
Atrial fibrillationCardiac disorders
Other adverse events (47 terms — click to expand)

ReactionSystemPembrolizumab/Vibostolimab…Pembrolizumab/Vibostolimab…Placebo + Docetaxel
DiarrhoeaGastrointestinal disorders
PruritusSkin and subcutaneous tissue disorders
AnaemiaBlood and lymphatic system disorders
AstheniaGeneral disorders
FatigueGeneral disorders
NauseaGastrointestinal disorders
AlopeciaSkin and subcutaneous tissue disorders
RashSkin and subcutaneous tissue disorders
Decreased appetiteMetabolism and nutrition disorders
ConstipationGastrointestinal disorders
DyspnoeaRespiratory, thoracic and mediastinal disorders
Oedema peripheralGeneral disorders
ArthralgiaMusculoskeletal and connective tissue disorders
Neutrophil count decreasedInvestigations
StomatitisGastrointestinal disorders
Weight decreasedInvestigations
Neuropathy peripheralNervous system disorders
COVID-19Infections and infestations
CoughRespiratory, thoracic and mediastinal disorders
VomitingGastrointestinal disorders
DysgeusiaNervous system disorders
PyrexiaGeneral disorders
MyalgiaMusculoskeletal and connective tissue disorders
HypothyroidismEndocrine disorders
InsomniaPsychiatric disorders
Lacrimation increasedEye disorders
HypokalaemiaMetabolism and nutrition disorders
Dry skinSkin and subcutaneous tissue disorders
EczemaSkin and subcutaneous tissue disorders
Abdominal painGastrointestinal disorders
Chest painGeneral disorders
Mucosal inflammationGeneral disorders
PneumoniaInfections and infestations
HyperglycaemiaMetabolism and nutrition disorders
ParaesthesiaNervous system disorders
Nail disorderSkin and subcutaneous tissue disorders
HyperthyroidismEndocrine disorders
Amylase increasedInvestigations
Blood creatinine increasedInvestigations
Lipase increasedInvestigations

Most-reported serious reactions: Pneumonia, Anaemia, Febrile neutropenia, Diarrhoea, COVID-19, Septic shock, Hip fracture, Cardiac failure.

Data from ClinicalTrials.gov NCT04725188 adverse events section.

Sponsor's own description

The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline placebo plus docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1)/ programmed cell death ligand 1(PD-L1) monoclonal antibody (mAb). MK-7684A is a coformulation product of pembrolizumab/vibostolimab. The dual primary hypotheses of the study are pembrolizumab/vibostolimab coformulation plus docetaxel and pembrolizumab/vibostolimab coformulation is superior to normal saline placebo plus docetaxel with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. · · 2021 · cited 166× · PMID 34367161 · DOI 10.3389/fimmu.2021.699895
  2. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.
    Joller N, Anderson AC, Kuchroo VK. · · 2024 · cited 159× · PMID 38354701 · DOI 10.1016/j.immuni.2024.01.010
  3. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
    Chu X, Tian W, Wang Z, Zhang J, et al · · 2023 · cited 147× · PMID 37291608 · DOI 10.1186/s12943-023-01800-3
  4. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.
    Zhou S, Yang H. · · 2023 · cited 64× · PMID 37090727 · DOI 10.3389/fimmu.2023.1129465
  5. Advances in molecular pathology and therapy of non-small cell lung cancer.
    Huang Q, Li Y, Huang Y, Wu J, et al · · 2025 · cited 43× · PMID 40517166 · DOI 10.1038/s41392-025-02243-6
  6. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.
    Lu C, Tan Y. · · 2024 · cited 43× · PMID 38596295 · DOI 10.1016/j.omton.2024.200773
  7. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors.
    Roy D, Gilmour C, Patnaik S, Wang LL. · · 2023 · cited 40× · PMID 37928556 · DOI 10.3389/fimmu.2023.1264327
  8. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
    Li MSC, Mok KKS, Mok TSK. · · 2023 · cited 37× · PMID 37675321 · DOI 10.21037/atm-22-4444

Verify or expand the search:

Other trials of Pembrolizumab/Vibostolimab coformulation

Trials testing the same drug.

Other recruiting trials for Metastatic Non Small Cell Lung Cancer

Currently open trials in the same condition.

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04725188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing